The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures

Lung Cancer

Volumn 61, Issue 1, 2008, Pages 91-96

  Fan, Jiang ^a   Wang, Lei ^b   Jiang, Ge Ning ^a   He, Wen Xin ^a   Ding, Jia An ^a  

^a TONGJI UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Non small cell lung cancer; Prognosis; Relative risk; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; SURVIVIN;

ARTICLE; CANCER LOCALIZATION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; IN SITU HYBRIDIZATION; LUNG NON SMALL CELL CANCER; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMATIC REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 45649083757     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.11.011     Document Type: Article

References (20)

1. Machtay M., and Jeremic B. Complex and controversial issues in locally advanced non-small cell lung carcinoma. Semin Surg Oncol 21 (2003) 128-137
2. Vischioni B., van der Valk P., Span S.W., Kruyt F.A., Rodriguez J.A., and Giaccone G. Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small cell lung cancer. Ann Oncol 15 (2004) 1654-1660
3. Akyurek N., Memis L., Ekinci O., Kokturk N., and Ozturk C. Survivin expression in pre-invasive lesions and non-small cell lung carcinoma. Virchows Arch 449 (2006) 164-170
4. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3 (2003) 46-54
5. Nachmias B., Ashhab Y., and Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 14 (2004) 231-243
6. Schimmer A.D. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 64 (2004) 7183-7190
7. Parmar M.K., Torri V., and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17 (1998) 2815-2834
8. Wang L., and Shao Z.M. Cyclin e expression and prognosis in breast cancer patients: a meta-analysis of published studies. Cancer Invest 24 (2006) 581-587
9. Lu B., Gonzalez A., Massion P.P., Shyr Y., Shaktour B., Carbone D.P., et al. Nuclear survivin as a biomarker for non-small cell lung cancer. Br J Cancer 91 (2004) 537-540
10. Shinohara E.T., Gonzalez A., Massion P.P., Chen H., Li M., Freyer A.S., et al. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer 103 (2005) 1685-1692
11. Vischioni B., Oudejans J.J., Vos W., Rodriguez J.A., and Giaccone G. Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther 5 (2006) 2905-2913
12. Atikcan S., Unsal E., Demirag F., Koksal D., and Yilmaz A. Correlation between survivin expression and prognosis in non-small cell lung cancer. Respir Med 100 (2006) 2220-2226
13. Falleni M., Pellegrini C., Marchetti A., Oprandi B., Buttitta F., Barassi F., et al. Survivin gene expression in early stage non-small cell lung cancer. J. Pathol 200 (2003) 620-626
14. Karczmarek-Borowska B., Filip A., Wojcierowski J., Smolen A., Pilecka I., and Jablonka A. Survivin antiapoptotic gene expression as a prognostic factor in non-small cell lung cancer: in situ hybridization study. Folia Histochem Cytobiol 43 (2005) 237-242
15. Kren L., Brazdil J., Hermanova M., Goncharuk V.N., Kallakury B.V., Kaur P., et al. Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol 12 (2004) 44-49
16. Monzo M., Rosell R., Felip E., Astudillo J., Sanchez J.J., Maestre J., et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small cell lung cancers. J. Clin Oncol 17 (1999) 2100-2104
17. Yoo J., Jung J.H., Lee M.A., Seo K.J., Shim B.Y., Kim S.H., et al. Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. J Kor Med Sci 22 (2007) 318-325
18. Zhou J.M., Zhou J.H., Deng Z.H., Zheng H., Jiang H.Y., and Cao H.Q. Expression of survivin and proliferating cell nuclear antigen in human non-small cell lung cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban 30 (2005) 544-548
19. Meert A.P., Martin B., Delmotte P., Berghmans T., Lafitte J.J., Mascaux C., et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 20 (2002) 975-981
20. Nakamura H., Kawasaki N., Taguchi M., and Kabasawa K. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 61 (2006) 140-145